Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses.
Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin.
November 15, 2018Malin investee company Novan announces positive Phase 2 trial data for its antiviral candidate SB206 for the treatment of molluscum contagiosum
January 15, 2019Immunocore names David Berman as Head of R&D
January 4, 2019Immunocore appoints Bahija Jallal as Chief Executive Officer